Journal of Clinical Psychopharmacology
Vagner Deuel O de Tavares, Kaike Thiê da Costa Gonçalves, Maria Luiza de Morais Barros et al.
1 citation
A meta-analysis of eleven studies found no significant correlation between the psychoactive (psychomimetic) effects of ketamine and clinical outcomes in mental illness, including depression. The overall correlation was r = 0.06, and for depression specifically r = 0.03, both non-significant. Sub-analyses accounting for patient disorders, intravenous administration, assessment instruments, and timing also yielded no significant findings. High heterogeneity was present. The analysis suggests that altered states of consciousness during ketamine sessions are not directly linked to clinical outcomes, but the limited number of studies and heterogeneity make this conclusion preliminary.
Current Psychology
June 1, 2026
Geovan Menezes de Sousa, Geissy Lainny de Lima-Araújo, Vagner Deuel de Oliveira Tavares et al.
Adults with major depressive disorder who report higher levels of dispositional mindfulness—the tendency to attend to present-moment experiences with openness and awareness—show fewer depressive and anxiety symptoms, better sleep quality, and higher self-esteem compared to those with lower trait mindfulness. In a cross-sectional study of 97 adults diagnosed with MDD, two clusters emerged: a High Trait group and a Low Trait group. The High Trait group had significantly lower depressive symptoms (d = 0.795) and anxiety symptoms (d = 0.739), and higher self-esteem (d = -0.586) and sleep quality (d = 0.460). These results suggest trait mindfulness may protect against poor mental health in depression.
Current Addiction Reports
February 21, 2026
Draulio B Araujo, Lucas O. Maia, Tiago Arruda Sanchez et al.
Preclinical and clinical evidence suggests that ayahuasca, a traditional Amazonian brew containing DMT and β-carbolines, may treat depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical studies indicate enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging shows decreased default mode network activity, increased functional connectivity and brain entropy, suggesting a flexible neural state and modulation of pathways related to neuroplasticity, inflammation, and stress response. The evidence is mainly observational, with users reporting emotional breakthroughs, increased self-awareness, and mystical experiences tied to therapeutic outcomes. Ayahuasca appears to target core psychological and neurobiological processes across disorders but requires caution in psychotic or bipolar individuals and should be administered with support. Randomized trials are needed to confirm efficacy and safety.
Translational Psychiatry
February 19, 2026
Luís Carlos Pereira, Wigínio Gabriel Lira-Bandeira, Andréa Silva Medeiros-Bandeira et al.
Chronic stress from social isolation in juvenile male marmosets reduces neuronal volume in the somatosensory cortex, a brain region implicated in depression. Ayahuasca, a psychedelic brew, given before and during isolation prevented this reduction, with treated animals showing neuronal volumes similar to non-stressed controls. Trends also suggested preserved cortical structure, though differences in neuronal density and overall cortical volume were not statistically significant. These results indicate ayahuasca may protect against stress-induced cortical atrophy and support further research into its therapeutic potential for stress-related psychiatric disorders, especially in adolescents.
Ponto Urbe
December 27, 2024
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
In February 2023, the U.S. Drug Enforcement Administration (DEA) released a 2020 report titled 'Ayahuasca: Risks to Public Health and Safety' to the legal team of the Church of the Eagle and the Condor, following Freedom of Information Act requests. This article challenges several claims in the DEA report, highlighting factual omissions, theoretical biases, and misinterpretations of existing data. The authors argue that the report minimizes ayahuasca's safety profile and therapeutic potential while overemphasizing risks, and fails to include current research demonstrating its potential benefits.
Journal of Affective Disorders
March 15, 2026
Patrícia Cavalcanti-Ribeiro, Lara Carvalho Araújo Melo De Souza, Vagner Deuel O de Tavares et al.
In a small open-label trial of 22 patients with treatment-resistant depression who received seven weekly subcutaneous doses of esketamine, those with elevated baseline C-reactive protein (CRP > 1 mg/L) showed significant reductions in CRP by week 4 and week 8, while patients without inflammation showed no change. By week 8, CRP levels in both groups were comparable. Although the inflammation group had a greater average reduction in depression severity (15.88 points on the MADRS scale versus 11.14 points), this difference was not statistically significant, and changes in CRP did not predict symptom improvement. Larger controlled studies are needed.